Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. (Q43605684)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Cristina Caffarra

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Andrea Cavazzoni

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Massimo Ippolito

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Maura Scarlattei

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pietro Spadaro

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Sebastiano Cosentino

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Fiorenza Latteri

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Marco Bartolotti

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Beatrice Bortesi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Roberta R Alfieri

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pier Giorgio Petronini

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Roberto Bordonaro

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Andrea Ardizzoni

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Hector J Soto Parra

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claudia Fumarola

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

21 November 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

73

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

299-307

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

https://scigraph.springernature.com/pub.10.1007/s00280-013-2356-x

0 references

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Metabolic imaging allows early prediction of response to vandetanib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Role of Akt/protein kinase B in metabolism.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Akt stimulates aerobic glycolysis in cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2356-X

21 January 2018

Identifiers

10.1007/S00280-013-2356-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24258456%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43605684&oldid=2101856831"